WaveStone Capital's Catherine Allfrey warns of profit downgrades to come as downturn hits

Catherine Allfrey of WaveStone Capital will be speaking at this year's Sohn Hearts & Minds Conference in Hobart, raising funds for medical research.

Glenda Korporaal

WaveStone Capital's Catherine Allfrey warns of profit downgrades to come as downturn hits

October 17, 2022
Catherine Allfrey of WaveStone Capital will be speaking at this year's Sohn Hearts & Minds Conference in Hobart, raising funds for medical research.
Read Transcript

Investors should brace for a string of profit downgrades as the global economic downturn hits Australia somewhere between early ­December and February.

That’s the view of WaveStone Capital director Catherine Allfrey, who says that corporates are in a twilight zone between the difficult times later this year and the strong earnings from the bounce out of the Covid-19 pandemic.

“We are waiting for the profit downgrades to come through in the US and Australia,” she said in an interview with The Australian.

“Rates are going to go up and consumption is going to be hit. It’s a question of when that is going to happen. Everyone knows the slowdown is coming,” she said.

“When we ask companies when they think it is going to happen, their answers range from early December to the back-to-school period in February.”

Ms Allfrey was speaking ahead of her first appearance at the annual Sohn Hearts & Minds investment conference to be held in Hobart in November.

The Sohn conference, which sees top fund managers give their stock tips, has raised more than $40m for medical research since it began in Australia in 2016, inspired by a similar event started in New York in 1995 in memory of Wall Street fund manager Ira Sohn, who died of cancer aged 29.

Ms Allfrey says her stock tip would be in line with the investment approach at WaveStone, which she co-founded in 2006, of looking for “quality companies with a sustainable competitive ­advantage at a reasonable price”.

“We have a very tight process (of stock selection),” she says. “We are value orientated.”

WaveStone, which is 32.5 per cent owned by the ASX-listed Challenger Group, has some $5bn in funds under management, $1bn in retail investment and another $4bn invested on behalf of super fund and institutional investors.

It invests in Australian companies and they must be profitable or expect to be within 12 months. The portfolio includes Qantas, ResMed, Woodside, Santos, CSL, Carsales and Aristocrat.

In selecting her stock tip, Ms Allfrey says she will also keep in mind Sohn’s preference for talking about companies that are seen as disruptive. “I’m looking at a few candidates, but I haven’t chosen one yet because the markets are so volatile,” she said.

Ms Allfrey said she and her WaveStone colleagues, including co-founder Raaz Bhuyan, were “frustrated” during the recent bull market seeing speculative companies were fetching high prices.

“We got very frustrated after Covid when interest rates went to zero. The stock prices of non-profitable companies, which we don’t invest in, went to the moon,” she said. “It was just ridiculous. But now that has been reversed, it has been fabulous. Now we have a cost of capital and a valuation discipline back in the market, which is really pleasing to see.”

Ms Allfrey said the pandemic changed the landscape for some companies in Australia, such as Qantas, which she says emerged from Covid-19 in a much stronger position in the market.

“Rule one of investing is never own an airline,” she said. “Rule two is don’t ignore rule one.”

But Qantas has bounced back strongly from the pandemic with increased market share, which will continue at least into the medium term while Virgin Australia, now in the hands of private equity, is focused on profitability, she said.

Ms Allfrey sees ResMed as another stock which has also come through Covid-19 well – one with more upside if it can get through issues with its supply chain.

When Ms Allfrey and her colleagues were setting up shop, they originally went with WaterStone.

But they got an irate email from a US hedge fund of the same name ordering them to drop the name. “When we got a second one we hurriedly changed the name,” she said. “But they didn’t survive the GFC and we are still here.”

 

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 17 October 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Investors should brace for a string of profit downgrades as the global economic downturn hits Australia somewhere between early ­December and February.

That’s the view of WaveStone Capital director Catherine Allfrey, who says that corporates are in a twilight zone between the difficult times later this year and the strong earnings from the bounce out of the Covid-19 pandemic.

“We are waiting for the profit downgrades to come through in the US and Australia,” she said in an interview with The Australian.

“Rates are going to go up and consumption is going to be hit. It’s a question of when that is going to happen. Everyone knows the slowdown is coming,” she said.

“When we ask companies when they think it is going to happen, their answers range from early December to the back-to-school period in February.”

Ms Allfrey was speaking ahead of her first appearance at the annual Sohn Hearts & Minds investment conference to be held in Hobart in November.

The Sohn conference, which sees top fund managers give their stock tips, has raised more than $40m for medical research since it began in Australia in 2016, inspired by a similar event started in New York in 1995 in memory of Wall Street fund manager Ira Sohn, who died of cancer aged 29.

Ms Allfrey says her stock tip would be in line with the investment approach at WaveStone, which she co-founded in 2006, of looking for “quality companies with a sustainable competitive ­advantage at a reasonable price”.

“We have a very tight process (of stock selection),” she says. “We are value orientated.”

WaveStone, which is 32.5 per cent owned by the ASX-listed Challenger Group, has some $5bn in funds under management, $1bn in retail investment and another $4bn invested on behalf of super fund and institutional investors.

It invests in Australian companies and they must be profitable or expect to be within 12 months. The portfolio includes Qantas, ResMed, Woodside, Santos, CSL, Carsales and Aristocrat.

In selecting her stock tip, Ms Allfrey says she will also keep in mind Sohn’s preference for talking about companies that are seen as disruptive. “I’m looking at a few candidates, but I haven’t chosen one yet because the markets are so volatile,” she said.

Ms Allfrey said she and her WaveStone colleagues, including co-founder Raaz Bhuyan, were “frustrated” during the recent bull market seeing speculative companies were fetching high prices.

“We got very frustrated after Covid when interest rates went to zero. The stock prices of non-profitable companies, which we don’t invest in, went to the moon,” she said. “It was just ridiculous. But now that has been reversed, it has been fabulous. Now we have a cost of capital and a valuation discipline back in the market, which is really pleasing to see.”

Ms Allfrey said the pandemic changed the landscape for some companies in Australia, such as Qantas, which she says emerged from Covid-19 in a much stronger position in the market.

“Rule one of investing is never own an airline,” she said. “Rule two is don’t ignore rule one.”

But Qantas has bounced back strongly from the pandemic with increased market share, which will continue at least into the medium term while Virgin Australia, now in the hands of private equity, is focused on profitability, she said.

Ms Allfrey sees ResMed as another stock which has also come through Covid-19 well – one with more upside if it can get through issues with its supply chain.

When Ms Allfrey and her colleagues were setting up shop, they originally went with WaterStone.

But they got an irate email from a US hedge fund of the same name ordering them to drop the name. “When we got a second one we hurriedly changed the name,” she said. “But they didn’t survive the GFC and we are still here.”

 

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 17 October 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Disclaimer: This material has been prepared by The Australian, published on Oct 17, 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 14, 2022

Think outside the box for green investment opportunities

James Miller, Portfolio Manager at Firetrail Investments, believes investors need to stop seeing the global decarbonisation push as a risk – and start seeing it as an opportunity.

Read More
November 14, 2022

Tim Carleton is backing the Aussie dream all the way

Carleton’s conviction will be on full display on Friday when he makes his third appearance at the Sohn Hearts & Minds Conference, where stock-pickers share their best ideas in the name of medical research.

Read More
November 10, 2022

Why this fundie is betting on luxury as recession fears mount

Bob Desmond is Head of Claremont Global and Co-Portfolio Manager. He will present at the Sohn Hearts & Minds Investment Leaders Conference in Tasmania on November 18.

Read More
November 7, 2022

This fundie couldn’t be happier with her portfolio

Joyce Meng is a presenter at this year’s Sohn Hearts & Minds Investment Leaders Conference on November 18, which takes place in Hobart and aims to raise money for medical research.

Read More
November 2, 2022

Equity Mates: Ricky Sandler, Eminence Capital

Founder, CIO and CEO of Eminence Capital Ricky Sandler talks about launching the $5.7bn asset manager, changing market structures and why he's participating in the SH&M conference.

Read More
November 1, 2022

Auscap Asset Management founder sticks to a winning formula

When Auscap Asset Management founder Tim Carleton tips a stock at the Sohn Hearts & Minds conference in Hobart, he doubts it will be a name that shocks investors.

Read More
October 31, 2022

Markets to enter ‘new phase’ with hidden risks lurking, says top stock picker Peter Cooper

One of Australia's most influential fund managers warns that investment markets have entered a “new phase” that is set to test the ­financial system.

Read More
October 31, 2022

Why Peter Cooper can’t wait for the next 30 years on markets

The veteran fund manager says the most uncertain period of his career will deliver huge opportunities – providing his firm can stick to its system.

Read More
October 30, 2022

Why this fundie is betting big on two losing companies

Speaking to the AFR before the SH&M conference, Sandler named global on-demand ride-sharing and food delivery service Uber Technologies among his top picks, alongside real estate marketplace Zillow.

Read More
October 27, 2022

Why this fundie is calling the peak for CBA shares

Jun Bei Liu is the lead Portfolio Manager at Tribeca Alpha Plus Fund and is set to present an investment idea at the Sohn Hearts & Minds Conference in Hobart on November 18.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.